Mankind Pharma Jumps 8% to Rs 2,500 as a 39% Profit Jump Wins Over Brokerages That Still Doubt the Pace

Mankind Pharma was one of the standout large-cap stocks on Tuesday. Shares rose as much as 8.13% to an intraday high of Rs 2,500 on the NSE, up from Monday's close of Rs 2,312, as investors and analysts worked through a September quarter that beat expectations on almost every line. The stock had already climbed about 5.4% intraday on Monday afternoon when the results came out, so the two-day move was roughly 11%. More than 1.6 million shares changed hands across the two exchanges by late morning, well above a typical session.

The rally stood out against a weak backdrop. The Sensex was down about 0.2% around midday, near 73,440, held back by IT stocks.

What the numbers showed

Consolidated net profit rose 39% from a year earlier to about Rs 711 crore, from Rs 512 crore. Revenue from operations grew 17.3% to Rs 4,338 crore. Operating profit (EBITDA) rose about 27% to Rs 1,175 crore, so margins widened by roughly two percentage points to around 27%. When margins expand that much on mid-teens sales growth, it usually means pricing, product mix or cost control did more of the work than volume.

Both of the company's main engines contributed. Domestic revenue grew 15.9%, helped by volume gains in prescription medicines, which account for most of Mankind's business. International revenue jumped 33%, driven by Mankind's own export business and by BSV, the specialty-drugs company it bought in 2024. The one weak area was consumer healthcare, Mankind's over-the-counter brands, where growth was muted.

Why brokerages are upbeat but cautious

Analysts agreed that the quarter was strong. They disagreed about how much of it will last. JPMorgan raised its EBITDA estimates by 3% to 4% on better visibility in Indian prescriptions and exports, but kept a Neutral rating. It said it wants to see Mankind outperform the Indian market more consistently and wants more clarity on the consumer business. It also noted that domestic growth was flattered by a low base from a year earlier.

Macquarie traced the earnings beat to higher revenue, a better-than-expected gross margin, operating leverage and lower research spending. Bernstein was the most cautious. It pointed to seasonally strong demand for acute-therapy drugs, a comparison base weakened by last year's GST changes, and little contribution so far from new brands. In its view, none of that justifies projecting the quarter's growth rate forward. Jefferies singled out the slow consumer business as the main soft spot.

That split explains the shape of the rally. The market is paying for a clean beat today, while the analysts who model the company are raising forecasts only modestly.

A different reaction from last week's pharma results

The response contrasts with what happened at Dr Reddy's on Monday, where the stock rose even though profit fell, because investors chose to look past a one-time charge. At Mankind there was nothing to look past. The beat came from the core domestic and export businesses rather than from accounting items.

What to watch

The next tests are whether domestic prescription growth holds up once the easy base disappears, and whether the consumer segment recovers. The size of the move matters as well. A two-day rally of about 11% in a large pharma stock prices in a good deal of the upgrade already, so further gains will probably depend on Mankind repeating this performance in the December quarter rather than on this one result.

This is an original summary based on public reporting. See our editorial policy for how we source, write, and correct our stories.